Baird lowered the firm’s price target on Leap Therapeutics to $11 from $20 and keeps an Outperform rating on the shares. The firm said its Q3 earnings update was uneventful, ahead of several clinical data readouts expected throughout 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LPTX:
